麝香保心丸与速效救心丸治疗冠状动脉粥样硬化性心脏病心绞痛的药物经济学评价OA

Objective To evaluate the efficacy and economy of Shexiang Baoxin Pill and Suxiao Jiuxin Pill in treating coronary heart disease.Methods The literature published on randomized controlled trials(RCTs)of Shexiang Baoxin Pill(treatment group)and Suxiao Jiuxin Pill(control group)in the treatment of coronary heart disease were included.After screening the literature and performing the quality evaluation,RevMan 5.4 software was used for Meta-analysis,and pharmacoeconomic evaluation was performed based on the results of this analysis.Results A total of 9 literatures were included.The difference between Shexiang heart-saving pill and quick-acting heart-saving pill was 2%,95%CI(-3%～6%)in symptom response rate and 20%,95%CI(-9%～48%)in ECG response rate.Under the national average,the incremental cost-effectiveness ratio of Shexiang heart-saving pills was-211.50(improved clinical symptoms)and-40.29(improved ECG results).In most provinces and cities across the country of China,the incremental cost-effectiveness ratio of Shexiang Bao Xin Pill to improve clinical symptoms and electrocardiogram results is negative,and even in provinces and cities across the country with positive incremental cost-effectiveness ratio,the value is relatively low.Conclusion Shexiang Baoxin Pill is more effective than Suxiao Jiuxin Pill in improving symptoms and ECG results in patients with coronary angina.On average across the country,Shexiang Baoxin Pill has the absolute economic advantage over Suxiao Jiuxin Pill.